Risk factors of Pancreatic Cancer in Vietnam: A Matched Case–Control Hospital-Based Study

Thuan Van Tran, MD, PhD1,2,3, Tu Van Dao, MD, PhD1,2,3, Khac-Dung Nguyen, Pharm, PhD1,3, To van TA, MD, PhD1,2,3, Khanh Truong Vu, MD, PhD4, Son Hong Trinh, MD, PhD5, Hoang Cong Nguyen, MD, PhD6, Oanh Thi Bui, Pharm, MPH1,3, Quang Tien Nguyen, MD, PhD1,3, Hoan Duc Vu, Pharm1,3, Hiep Le Nguyen, Pharm1,3, and Huong Thanh Tran, MD, PhD1,2,3

Abstract

**Background:** Data about the risk factors and pancreatic cancer in developing countries remain limited. We investigated for the first time the role of a number of risk factors (family cancer history, smoking, alcohol consumption, diabetes, inflammation disease, HBV infection) associated with pancreatic cancer among Vietnamese patients.

**Methods:** We included all patients hospitalized at 4 Northern Vietnamese hospitals (Vietnam National Cancer Hospital, Bach Mai, Viet Duc, Thai Nguyen) and diagnosed with pancreatic cancer during the period from 2017 to 2019. Risk factors of eligible patients were collected and assessed the associations using a matched control study and logistic regression model analysis.

**Results:** We identified 196 patients with diagnosis of pancreatic cancer of which 114 males and 82 females. The average age of the patient at the time of diagnosis was 58.28 years (standard deviation of 12.94, ranging from 25 to 87). Most of patients were diagnosed at advanced stage (85%). Smoking, diabetes, inflammation disease significantly increased the cancer risks (OR and 95% CI were 2.42 (1.38-4.37), 3.09 (1.54-6.68), 2.21 (1.42-3.45), respectively). HBV infection demonstrated a significant link with pancreatic cancer in univariate model (OR = 2.94 (1.08-9.36)), but not in multivariate model. However, cancer family history and alcohol drinkers did not show any significantly increased risk related to pancreatic cancer.

**Conclusions:** Our finding showed smoking, diabetes, inflammation disease significantly increased the risk of pancreatic cancer in Vietnam.

**Keywords**
pancreatic cancer, risk factors, smoking, diabetes, Vietnam

Received July 31, 2020. Received revised December 01, 2020. Accepted for publication December 30, 2020.

**Background**

Pancreatic cancer is a poor prognostic cancer and considered as “a silent killer.” Due to the lack of early detection, most pancreatic cancers are diagnosed at an advanced stage (approximately 50% of all pancreatic cancers are diagnosed after metastases). In fact, no strong evidence of an effective treatment for localized pancreatic cancer has been found, and no screening policy for pancreatic cancer has been well developed.
established until now. Worldwide, pancreatic cancer caused 432,242 deaths in 2018 (with 458,918 cases) according to GLOBOCAN 2018. In the United States, the incidence of new pancreatic cancer in men and women ranked ninth and tenth, respectively; however, the mortality rate is even higher, ranking fourth for both male and female. Pancreatic cancer has the lowest overall survival rate after 5 years (5%-6%) and the shortest life expectancy (6 months) in comparison to other cancers. In addition, while the new incidence and mortality rates of other cancers decreased, the incidence of pancreatic cancer increased by 1.5% per year, with no significant improvement in mortality rate over the past 4 decades. It is important to note the increasing incidence, because it is possibly due to environmental factors. Actually, mortality increases in parallel with the incidence because there is no effective treatment, whatever the cancer stage. The choices of pancreatic cancer treatment are also limited. Indeed, for advanced stages, chemotherapeutic agents are mostly inefficient. Even at localized stages, 5-year survival rate for potentially curative resection is only about 20% (39.4% for localized cancer and 13.3% for regional cancer). Hence, there is an urgent need to identify risk factors to possibly control pancreatic cancer. In fact, there were more than 50 specific modifiable and non-modifiable risk factors related to pancreatic cancer that were well described in 100 meta-analytical or pooled reports. Fortunately, about two-thirds of these risk factors are potentially modifiable. Smoke, alcohol consumption, chronic pancreatitis, obesity, diabetes mellitus, unhealthy dietary behavior, and physical activity could majorly contribute to the risk of pancreatic cancer. In this study, we intended to assess the association between some risk factors and pancreatic cancer to evaluate whether the known association between these risk factors and pancreatic cancer could be replicated in our cohort study related to Vietnamese patients.

Methods

Data Source and Pancreatic Cancer Case and Control Identification

We identified all patients aged 18 years or above who were diagnosed with primary pancreatic cancer and hospitalized at 4 Northern Vietnamese hospitals (Vietnam National Cancer Hospital, Bach Mai, Viet Duc, and Thai Nguyen) during the period from January 1, 2017, to June 30, 2019. We then only included patients with the confirmed diagnosis of pancreatic cancer based on histopathology, computed tomography (CT), magnetic resonance imaging with magnetic resonance cholangiopancreatography, or endoscopic ultrasound. Primary tumor (T), regional lymph nodes (N), and metastasis (M) status were evaluated using the criteria of AJCC 7th Cancer Staging Manual. Disease stage was identified by assessment of TNM mentioned above. We excluded patients who had a history of any other cancer at any time prior to the pancreatic cancer diagnosis date or who disagreed to participate in the study. The calculated sample size was not required because we applied the convenience sampling method, and this was a preliminary study based on Vietnamese population.

For each pancreatic cancer case, we randomly selected one control subject from the cohort of healthy control patients who had a cancer screening at our hospitals without a diagnosis of pancreatic cancer or of any other cancers. The chosen control was also matched on age, sex, and calendar time (i.e., using the same index date as for cases) with the corresponding case.

Medical records reviews followed by patient interviews (if needed in case of missing data) have been carefully conducted to identify sociodemographic characteristics, lifestyle factors including tobacco and alcoholism situation (alcohol consumption with amount of alcohol intake at least 30 g/day or 150 g/week), and history of selected medical conditions including diabetes, inflammation diseases (asthma, autoimmune diseases, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, transplant rejection, or other similar conditions), and hepatitis B virus (HBV) infection.

The study was performed in accordance with the Declaration of Helsinki, and written informed consent was obtained from patients before participating in the study. The study protocol was reviewed and approved by the Institutional Review Board of Vietnam National Cancer Hospital. Patients were given a full explanation of the purposes and nature of study, and they could voluntarily withdraw at any time during the research process. The collected data would be kept confidentially for the purpose of research only.

Statistical Analyses

We mainly analyzed the information related to age, gender, smoking, alcohol drinking, diabetes, inflammation disease, and HBV infection of all eligible patients. Continuous variables were described by mean (±SD), and categorical variables were described by frequency and percentage. For comparison of parameters between case and control groups, Fisher’s exact test or chi-square tests were applied for categorical variables, and Student’s test (t-test) was applied for continuous variables. Odds ratios (OR) were used to describe the links of pancreatic cancer and risk factors. Univariate and multivariate logistic regression models associated with selected lifestyles and other suggested risk factors were used to estimate OR and its 95% confidence interval (CI). Correspondingly, variables like age (continuous variable), gender (male, female), family history of cancer (yes, no), history of diabetes (yes, no), previous alcohol drinking (yes, no), history of smoking (yes, no), any inflammation disease (yes, no), and HBV infection (yes, no) were included in the models. Factors significantly increase the risk of pancreatic cancer if the lower bound of 95% CI is >1 and significantly reduce the risk of pancreatic cancer if the upper bound of 95% CI is <1. R version 3.4.4 (released on March 15, 2018) was used to perform the statistical analysis. In order to have similar characteristics in terms of age, gender, and calendar time between cases and controls, we used the random pairing technique (1:1 ratio) by using the MatchIt package based on R.
Results
We identified 196 pancreatic cancer patients and 196 matched controls for the analysis. The mean age of the case group and control group was 59 years, with a sex ratio (male/female) of 1.76 (Table 1). We also found pancreatic cancer patients mainly aged from 50 to 69 years (58.1%). Among pancreatic cancer patients, 149 cases (78%) were newly diagnosed, and 43 cases (22%) were diagnosed before January 2017. Most of them were diagnosed at an advanced stage (stage III-IV, accounting for 85% of patients) (Table 2). CT was the main diagnosis method for pancreatic cancer (69%), followed by histopathology (28%).

Table 3 presents the characteristics of some selected risk factors. The results show that patients in the control group had more family history of cancer than pancreatic cancer patients. Especially in the women subgroup, there is a higher frequency of smoking, alcohol consumption, and diabetes among pancreatic cancer patients. Overall, we found significant differences in terms of presence of family cancer history (p < 0.001) between cases and controls, whereas no difference was found between the 3 groups for tobacco, alcohol consumption, and diabetic comorbidity.

Table 4 presents ORs and their 95% CI of pancreatic cancer calculated using univariate and multivariate models for selected risk factors. Only family history of cancer did not increase the risk in both adjusted models. Smoking, past or present history diabetes, and inflammation disease significantly increased the risks of cancer (ORs were 2.42 (1.38-4.37), 3.09 (1.54-6.68), and 2.21 (1.42-3.45), respectively). Current alcohol drinkers did not show any significantly increased risk related to pancreatic cancer in the univariate and multivariate models.

Discussion
Majority of pancreatic cancer cases are diagnosed at the advanced stage; therefore, curative treatment is usually inapplicable. Until now, there is currently no official guideline nor consensus on screening individuals for this disease. By analyzing the pathogenesis related to both genetic and environmental factors in this study, we could contribute to the existing knowledge of pancreatic cancer in the context of developing countries.

In our matched case–control study based on Vietnamese patients, alcohol consumption and diabetes were identified as risk factors of pancreatic cancer. The risk related to diabetes was even more significant in the women subgroup, whereas it mitigated in the men subgroup. Until now, the mechanism of increased risk of pancreatic cancer in people with diabetes is still unknown. However, the link between diabetes and the risk of pancreatic cancer has been reported in many recent studies. In the study of Gupta et al., the incidence of pancreatic cancer in diabetic patients was 2.2 times higher than that of nondiabetic patients and highest in the first 2 years since the diagnosis of diabetes. The incidence of pancreatic cancer significantly decreased in the following years of follow-up (p < 0.0008). The relationship between diabetes and pancreatic cancer is most pronounced in younger patients. In an 11-year follow-up study of 2,186,196 Israeli population, hazard ratios (HR) for

### Table 1. Age and Gender Distribution of Pancreatic Cancer Cases and Controls.

| Age category (%) | Male Cancer (N = 114) | Male Control (N = 118) | Female Cancer (N = 78) | Female Control (N = 78) |
|------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| 20-29            | 2 (1.8)               | 0 (0.0)               | 5 (6.1)               | 0 (0.0)               |
| 30-39            | 5 (4.4)               | 1 (0.8)               | 4 (4.9)               | 4 (5.1)               |
| 40-49            | 17 (14.9)             | 18 (15.3)             | 12 (14.6)             | 18 (23.1)             |
| 50-59            | 32 (28.1)             | 41 (34.7)             | 10 (12.2)             | 12 (15.4)             |
| 60-69            | 43 (37.7)             | 43 (36.4)             | 29 (35.4)             | 32 (41.0)             |
| 70-79            | 14 (12.3)             | 15 (12.7)             | 16 (19.5)             | 12 (15.4)             |
| 80-89            | 1 (0.9)               | 0 (0.0)               | 6 (7.3)               | 0 (0.0)               |

### Table 2. Clinical Characteristics of Pancreatic Cancer Patients.

| Clinical characteristics | Number (%) (N = 196) |
|--------------------------|----------------------|
| **Situation of diagnosis** |                       |
| Previously diagnosed PC  | 43 (22%)             |
| Newly diagnosed PC       | 149 (78%)            |
| Unknown                  | 4                    |
| **AJCC stage**           |                       |
| IA                       | 1 (0.8%)             |
| IB                       | 3 (2.4%)             |
| IIA                      | 3 (2.4%)             |
| IIB                      | 11 (9.9%)            |
| III                      | 27 (22%)             |
| IV                       | 78 (63%)             |
| Unknown                  | 73                   |
| **Diagnosis method**     |                       |
| CT                       | 129 (69%)            |
| MRI                      | 4 (2.2%)             |
| Histopathology           | 53 (28%)             |
| Other methods            | 11                   |
pancreatic cancer were significant and nearly the same between men and women (HR = 3.25, 95% CI 2.85-3.69 and HR = 3.10, 95% CI 2.72-3.52, respectively). However, in a Czech Republic study, the proportion of pancreatic cancer in diabetic men was significantly higher than that of women (43.9% versus 25%), while this rate in the group without diabetes is equivalent (22.1% compared to 17.2%). Once again, our finding confirmed the diabetes-related pancreatic cancer risk and is in favor that women are at higher risk than men (see Supplementary Material 1).

It is well known that smoking is associated with pancreatic cancer, as the continuation and cessation of smoking were correlated with the increase and plateau of the disease incidence in Japan for about 40 years of surveillance. Research showed that quitting smoking immediately could decrease 15%-20% cases of pancreatic cancer and mortality rate. Hence, nontobacco exposure is the best way to reduce the incidence of pancreatic cancer.

In a pool analysis of 6507 pancreatic cases and 12,890 controls, Bosetti et al. pointed out an increase of pancreatic cancer risk in smokers with an OR of 2.2 for current smokers and only 1.2 for former smokers, and the risk was strongly related to the amount and duration of tobacco exposure. A cohort study in the Netherlands conducted by Heinen et al. demonstrated that the risk of pancreatic cancer increased for every period of 10 years of smoking (HR = 1.15, 95% CI 1.08-1.22) and for every amount of 10 cigarettes/day (HR = 1.08, 95% CI 0.98-1.19). It is also commonly accepted that the impact of smoking on cancer may vary between populations. Therefore, some ethnic differences may exist regarding susceptibility to the effects of smoking. In a study by the International Agency for Research on Cancer, smoking was confirmed to be highly associated with pancreatic cancer and correlated with smoking duration and number of cigarettes per day. In a meta-analysis including 82 studies, the risk of pancreatic cancer was significantly elevated for current and former smokers (risk relative values were 1.74 and 1.2, accordingly). A recent meta-analysis publication of Ben et al. involving 20 studies and 2,517,623 participants also showed similar results, in both the Western regions and the Asia-Pacific regions. Our finding was in favor of the results above.

Regarding alcohol use, research shows that alcohol intake was significantly associated with an increased risk of pancreatic cancer, especially high alcohol intake. The results of a prospective study conducted by Gapstur et al. and a pooled analysis of 10 case-control studies in the International Pancreatic Cancer Case–Control Consortium conducted by Lucenteforte et al. strongly pointed out that alcohol consumption, particularly heavy intake, was an independent risk factor for pancreatic cancer regarding smoking status. In a pooled analysis of 14 cohort studies, consuming 30 g or more of alcohol daily increases the risk of pancreatic cancer compared with non-alcohol users (pooled multivariate RR = 1.22, 95% CI 1.03-1.45). Despite no clear biological mechanism and association of alcohol intake and pancreatic cancer, alcohol drinking remains an important cause of chronic pancreatitis, which could induce pancreatic cancer. However, our finding did not show a similar result. Indeed, the association of the risk factor with pancreatic cancer could vary among populations due to difference in sociodemographic characteristics and lifestyles.

### Table 3. Description of Some Risk Factors of Pancreatic Cancer Cases and Controls.

| Risk Factor                  | Overall                  | Male                  | Female                  |
|-----------------------------|--------------------------|-----------------------|-------------------------|
|                             | Cancer | Control | p     | Cancer | Control | p     | Cancer | Control | p     |
| Cancer family history (%)   | No     | 191 (97.4) | 144 (74.6) | <0.001 | 112 (98.2) | 88 (75.9) | <0.001 | 79 (96.3) | 56 (72.7) | <0.001 |
|                             | Yes    | 5 (2.6)   | 49 (25.4)  |        | 2 (1.8)   | 28 (24.1)  |        | 3 (3.7)   | 21 (27.3)  |        |
| Tobacco smoking (%)         | No     | 116 (68.2) | 116 (60.4) | 0.15   | 52 (53.6)  | 43 (36.4)  | 0.017  | 64 (87.7) | 73 (98.6)  | 0.021  |
|                             | Yes    | 54 (31.8)  | 76 (39.6)  |        | 45 (46.4)  | 75 (63.6)  |        | 9 (12.3)  | 1 (1.4)    |        |
| Alcohol drinking (%)        | No     | 102 (60.0) | 127 (66.5) | 0.242  | 42 (42.9)  | 55 (47.0)  | 0.637  | 60 (83.3) | 72 (97.3)  | 0.01   |
|                             | Yes    | 68 (40.0)  | 64 (33.5)  |        | 56 (57.1)  | 62 (53.0)  |        | 12 (16.7) | 2 (2.7)    |        |
| Diabetes (%)                | No     | 161 (82.1) | 168 (89.4) | 0.061  | 94 (82.5)  | 97 (86.6)  | 0.497  | 67 (81.7) | 71 (93.4)  | 0.048  |
|                             | Yes    | 35 (17.9)  | 20 (10.6)  |        | 20 (17.5)  | 15 (13.4)  |        | 15 (18.3) | 5 (6.6)    |        |

### Table 4. Risk Factors Associated With Pancreatic Cancer.

| Risk factors                  | Cancer | Control | p     | Male | Control | p     | Female | Control | p     |
|-------------------------------|--------|---------|-------|------|---------|-------|--------|---------|-------|
| Tobacco smoking, Yes          | 2.42 (1.38-4.37) | 2.94 (1.59-5.56) | 3.59 (1.72-7.69) | 1.48 (0.91-2.42) | 1.73 (1.0-3.0) | 1.27 (0.62-2.61) | 3.09 (1.54-6.68) | 3.05 (1.51-6.58) | 2.54 (1.10-6.14) | 2.21 (1.42-3.45) | 2.20 (1.41-3.44) | 3.02 (1.76-5.30) | 2.94 (1.08-9.36) | 2.95 (1.08-9.37) | 2.14 (0.69-7.57) | 0.6 (0.18-1.84) | 0.59 (0.19-2.00) | 0.44 (0.11-1.48) |

- The multivariate regression model is adjusted by age and gender.
- The multivariate regression model was adjusted by age, gender, family history of cancer, diabetes, smoking, inflammation disease and HBV infection.
The risk of pancreatic cancer increases with age, with 80% of cases diagnosed at age 60-80. Only about 10% of patients have pancreatic cancer under 50 years old, and pancreatic cancer is a rare condition at the age of under 25. In the United States, 81.4% of patients are diagnosed with pancreatic cancer over 60 years old. In the past 6 decades, only 1 in every 100,000 Americans aged 20-29 had pancreatic cancer; however, at the age of over 80, this figure reached 87.2 in every 100,000 people. People over the age of 70 have 4 times the risk of pancreatic cancer compared to those under 50 years old. However, in our study, we found 86 (43.9%) patients under 50 years old, of which 3 patients are 25 years or below, as well as a striking observation in young patients with pancreatic cancer. Compared to a series of patients from Western countries, our patients were relatively younger at the time of diagnosis. Our findings were also different from the results of a study conducted by Hana et al. in Kuwait in terms of patient age and were not in favor of the general concept about this cancer: the incidence rates were the highest in older than 70 years and increased with age. However, similar to Western countries, pancreatic cancer in this region occurs more in men than in women. This is probably related to the higher prevalence of smoking and some other risk factors among males.

Family history presents as one of the risk factors of pancreatic cancer, and about 5%-10% of individuals with pancreatic cancer report a history of pancreatic cancer in first-degree relatives. In people with a family history of pancreatic cancer, the risk of pancreatic cancer was 1.68-30 times higher than those without a family history of pancreatic cancer. However, the role of family history of cancer did not show a similar result in our study.

Many human cancers result directly from chronic inflammation, which has been shown to play an important role in pancreatic carcinogenesis for more than 150 years, especially chronic pancreatitis. Although the mechanisms involved in inflammation associated with pancreatic cancer are not completely understood, the results of our study suggest a link between any inflammation situation and pancreatic cancer. Further studies are required to confirm these risk factors as well as give clues to the interactions of other environmental or endogenous factors related to pancreatic cancer, including the genetic background.

Conclusions
In conclusion, we observed significant associations of smoking, diabetes, and inflammation disease to pancreatic cancer risk in Vietnam. However, alcohol consumption and family history of cancer did not show an increased risk of pancreatic cancer. Further studies are required to confirm these risk factors as well as give clues to the interactions of other environmental or endogenous factors related to pancreatic cancer, including the genetic background.

Authors’ Note
Thuan Van TRAN, MD, PhD and Tu Van DAO, MD, PhD, equally major contributed to this work. Our study was approved by National Ethic Committee (approval No.3165/QD-BKHCN, 26th October 2016). All patients provided written informed consent prior to enrollment in the study.

Acknowledgments
The authors would like to thank Pr Guilhem Bousquet (MD, PhD) for critically revising the manuscript. The authors would also like to thank ENAGO for the English language review.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received the government financial support for the research related to content of this article [KC.10/16-20].
Supplemental Material

Supplemental material for this article is available online.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. doi:10.3322/caac.21332

3. Genkinger JM, Spiegelman D, Anderson KE, et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009;18(3):765-776. doi:10.1158/1055-9965.EPI-08-0880

4. Brune KA, Lau B, Palmisano E, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102(2):119-126. doi:10.1093/jnci/djp466

5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi:10.3322/caac.21166

6. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249. doi:10.1038/nmeth0410-248

7. SEER. Cancer of the pancreas—cancer stat facts. SEER. Published 2020. Accessed July 7, 2020. https://seer.cancer.gov/statfacts/html/pancreas.html

8. Bekaii-Saab T, El-Rayes B, eds. Current and Emerging Therapies in Pancreatic Cancer. Springer International Publishing; 2018. doi:10.1007/978-3-319-58256-6

9. Maisonneuve P, Lowenfels A. Epidemiology and prospects for prevention of pancreatic cancer. In: Neoptolemos JP, Urrutia R, Abbruzzese JL, Bächler MW, eds. Pancreatic Cancer. Springer; 2018, pp. 3-18. doi:10.1007/978-1-4939-7193-0_73

10. Capasso M, Franceschi M, Rodriguez-Castro KI, et al. Epidemiology and risk factors of pancreatic cancer. Acta Biomed. 2018;89(8-S):141-146. doi:10.23750/abm.v89n9-S.7923

11. Naudin S, Viallon V, Hashim D, et al. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study. Eur J Epidemiol. 2020;35(10):975-986. doi:10.1007/s10654-019-00559-6

12. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10-27. doi:10.14740/wjoln1166

13. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934-947. doi:10.1016/S2468-1253(19)30347-4

14. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694-9705. doi:10.3748/wjg.v22.i44.9694

15. Edge SB, American Joint Committee on Cancer, American Cancer Society, eds. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th ed. Springer; 2010.

16. CRAN. R: The R project for statistical computing. Published 2017. Accessed August 31, 2017. https://www.r-project.org/

17. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15(3):199-236. doi:10.1093/pan/mpl013

18. Gupta S, Vittinghoff E, Bertenthal D, et al. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol. 2006;4(11):1366-1372. doi:10.1016/j.cgh.2006.06.024

19. Dankner R, Freedman LS, Gerstein HC, Roth J, Keinan-Boker L. Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. Diabetes Metab Res Rev. 2018;34(6):e3018. doi:10.1002/dmr.3018

20. Trna J, Dítě P, Adamcová A, Crawford BJ, Hermanová M. Diabetes mellitus in pancreatic cancer patients in the Czech Republic: sex differences. Exp Diabetes Res. 2012;2012:414893. doi:10.1155/2012/414893

21. Mulder I, Hoogenveen RT, van Genugten ML, et al. Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. Eur J Gastroenterol Hepatol. 2002;14(12):1343-1353. doi:10.1097/00042737-200212000-00010

22. Heinen MM, Verhage BAJ, Goldbohm RA, van den Brandt PA. Active and passive smoking and the risk of pancreatic cancer in the Netherlands Cohort Study. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1612-1622. doi:10.1158/1055-9965.EPI-10-0121

23. Adair T, Hoy D, Dettrick Z, Lopez AD. Tobacco consumption and pancreatic cancer mortality: what can we conclude from historical data in Australia? Eur J Public Health. 2012;22(2):243-247. doi:10.1093/eurpub/ckr048

24. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23(7):1880-1897. doi:10.1093/annonc/mdr314

25. Mulder I, Hoogenveen RT, van Genugten ML, et al. Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. Eur J Gastroenterol Hepatol. 2002;14(12):1343-1353. doi:10.1097/00042737-200212000-00010

26. Heinen MM, Verhage BAJ, Goldbohm RA, van den Brandt PA. Active and passive smoking and the risk of pancreatic cancer in the Netherlands Cohort Study. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1612-1622. doi:10.1158/1055-9965.EPI-10-0121

27. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23(7):1880-1897. doi:10.1093/annonc/mdr314
29. Wang Y-T, Gou Y-W, Jin W-W, Xiao M, Fang H-Y. Association between alcohol intake and the risk of pancreatic cancer: a dose-response meta-analysis of cohort studies. *BMC Cancer*. 2016;16(1):212. doi:10.1186/s12885-016-2241-1

30. Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). *Ann Oncol*. 2012;23(2):374-382. doi:10.1093/annonc/mdr120

31. Gapstur SM, Jacobs EJ, Deka A, McCullough ML, Patel AV, Thun MJ. Association of alcohol intake with pancreatic cancer mortality in never smokers. *Arch Int Med*. 2011;171(5):444-451. doi:10.1001/archinternmed.2010.536

32. Al-Majed HT, El-Basmi AA, Al-Mohannadi SH, Govindan R, Rajakumari GB. Pancreatic cancer: incidence, clinical profile, and frequency of associated factors in Kuwait. *Alexandria J Med*. 2013;49(1):75-80. doi:10.1016/j.ajme.2012.06.004

33. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. *Aliment Pharmacol Ther*. 2006;24(1):87-94. doi:10.1111/j.1365-2036.2006.02961.x

34. Chang KJ, Parasher G, Christie C, Largent J, Anton-Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. *Cancer*. 2005;103(2):349-357. doi:10.1002/cncr.20771

35. Pourhoseingholi MA, Ashtari S, Hajizadeh N, Fazeli Z, Zali MR. Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: major patterns in GLOBACON 2012. *Gastroenterol Hepatol Bed Bench*. 2017;10(4):245-257.

36. Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. *Fam Cancer*. 2009;8(2):109-117. doi:10.1007/s10689-008-9214-8

37. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. *Arch Pathol Lab Med*. 2009;133(3):365-374. doi:10.1043/1543-2165-133.3.365

38. Fernandez E, La Vecchia C, D’Avanzo B, Negri E, Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. *Cancer Epidemiol Biomarkers Prev*. 1994;3(1):209-212.

39. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. *Br J Cancer*. 1999;80(11):1830-1837. doi:10.1038/sj.bjc.6690607

40. Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. *Clin Cancer Res*. 2001;7(3):738-744.

41. Fehringer G, Gallinger S, Borgida A, et al. The association of family history of cancer and medical history with pancreatic cancer risk. *Pancreas*. 2014;43(5):812-814. doi:10.1097/MPA.0000000000000126

42. Shadhu K, Xi C. Inflammation and pancreatic cancer: an updated review. *Saudi J Gastroenterol*. 2019;25(1):3-13. doi:10.4103/sjg.SJG_390_18

43. Ben Q, Li Z, Liu C, et al. Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: a case-control study from China. *Pancreas*. 2012;41(3):435-440. doi:10.1097/MPA.0b013e31822ca176

44. Nguyen VT-T, McLaws M-L, Dore GJ. Highly endemic hepatitis B infection in rural Vietnam. *J Gastroenterol Hepatol*. 2007;22(12):2093-2100. doi:10.1111/j.1440-1746.2007.05010.x